Total Liver Disease — Total revenues
Gilead Sciences Total Liver Disease — Total revenues decreased by 9.2% to $767.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.2%, from $758.00M to $767.00M. Over 3 years (FY 2022 to FY 2025), Total Liver Disease — Total revenues shows an upward trend with a 4.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market share, successful product adoption, or effective pricing strategies within the liver disease therapeutic area, while a decrease may signal increased competition, patent expirations, or declining patient demand.
Detailed definition
This metric represents the total gross revenue generated from the sale of pharmaceutical products specifically indicated...
Peer comparison
Comparable to revenue segments for specialized therapeutic areas in other biopharmaceutical firms, such as oncology or immunology divisions, where performance is driven by drug efficacy and market access.
gild_segment_total_liver_disease_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $699.50M | $699.50M | $699.50M | $699.50M | $696.00M | $696.00M | $696.00M | $696.00M | $737.00M | $832.00M | $733.00M | $719.00M | $758.00M | $795.00M | $819.00M | $845.00M | $767.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -0.5% | +0.0% | +0.0% | +0.0% | +5.9% | +12.9% | -11.9% | -1.9% | +5.4% | +4.9% | +3.0% | +3.2% | -9.2% |
| YoY Change | — | — | — | — | -0.5% | -0.5% | -0.5% | -0.5% | +5.9% | +19.5% | +5.3% | +3.3% | +2.8% | -4.4% | +11.7% | +17.5% | +1.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's total liver disease — total revenues?
- Gilead Sciences (GILD) reported total liver disease — total revenues of $767.00M in Q1 2026.
- How has Gilead Sciences's total liver disease — total revenues changed year-over-year?
- Gilead Sciences's total liver disease — total revenues increased by 1.2% year-over-year, from $758.00M to $767.00M.
- What is the long-term trend for Gilead Sciences's total liver disease — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's total liver disease — total revenues has grown at a 4.8% compound annual growth rate (CAGR), from $2.80B to $3.22B.
- What does total liver disease — total revenues mean?
- The total sales revenue generated from the company's portfolio of liver disease treatments.